What is Vor Biopharma's G&A?

Vor Biopharma (VOR) reported G&A of $17.57M in Q1 2026.

How has Vor Biopharma's G&A changed year-over-year?

Vor Biopharma's G&A increased by 166.5% year-over-year, from $6.59M to $17.57M.

What is the long-term trend for Vor Biopharma's G&A?

Over 4 years (2021 to 2025), Vor Biopharma's G&A has grown at a 23.6% compound annual growth rate (CAGR), from $21.49M to $50.11M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Vor Biopharma VOR G&A

G&A at other companies

Dianthus TherapeuticsDNTH

$12.47M+69.9%

Cullinan Therapeutics, Inc.CGEM

$11.57M-14.5%

Design Therapeutics, Inc.DSGN

$5.33M+5.7%

Avalo TherapeuticsAVTX

$6.85M+23.6%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Janux TherapeuticsJANX

$11.13M+13.1%

Other financials

Income statement

See full

Operating income-$35.2M-5.6%

Net income-$219.6M-576%

EPS (diluted)-$5.11+1.9%

Balance sheet

See full

Cash & equivalents$169.9M+239%

Total debt$2.9M-90.5%

Total equity-$150.4M-328%

Total assets$506.7M+364%

Cash flow

See full

Operating cash flow-$38.2M-23.1%

CapEx$48.0K-79.2%

Free cash flow-$38.3M-22.4%

Valuation

See full

Market cap$784.61M+2,513%

Enterprise value$617.68M+5,639%

Returns & leverage

See full

Return on equity-125.4%+671pp

Debt / equity0.5×+0.2×

Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vor Biopharma's G&A?: Vor Biopharma (VOR) reported G&A of $17.57M in Q1 2026.
How has Vor Biopharma's G&A changed year-over-year?: Vor Biopharma's G&A increased by 166.5% year-over-year, from $6.59M to $17.57M.
What is the long-term trend for Vor Biopharma's G&A?: Over 4 years (2021 to 2025), Vor Biopharma's G&A has grown at a 23.6% compound annual growth rate (CAGR), from $21.49M to $50.11M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.